INX-315

• Description :

  INX-315 is an orally active and selective CDK2 inhibitor that induces cell cycle arrest in the G1 phase. INX-315 reduces CDK2 substrate phosphorylation and inhibits tumor growth in a dose-dependent manner in xenograft mouse models. INX-315 may be used in cancer research[1].

• UNSPSC :

  12352005

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/inx-315.html

• Purity :

  99.75

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(NN1)C2(CCCCC2)N(C1=C3)C4=C3C=NC(NC5=CC=C(S(=O)(N)=O)C=C5)=N4

• Molecular Formula :

  C19H21N7O3S

• Molecular Weight :

  427.48

• References & Citations :

  [1]Dietrich C, et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov. 2023 Dec 4. |[2]Trub A G, et al. INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers[J]. Cancer Research, 2023, 83 (7_Supplement) : 5994-5994.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [2745060-92-6]